Blocking GDF-15 signaling with a monoclonal antibody led to participants feeling less unwell and eating more, resulting in less weight loss.

“So now what pharmaceutical companies have tried to do is to say okay let's block GDF-15 signaling so people don't feel like Uh and so there's this one trial that was published in the New England journal uh last year and they show as expected if you block GDF-15 with a monoconal antibbody u people don't feel as terrible and they eat a little more and they don't lose as much weight.”